Neurodegenerative disorders: Insights from the nematode Caenorhabditis elegans

Neurobiology of Disease

Volumn 40, Issue 1, 2010, Pages 4-11

  Dimitriadi, Maria ^a   Hart, Anne C ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Amyotrophic lateral sclerosis; C. elegans; Huntington's disease; Neurodegeneration; Parkinson's disease; Protein aggregation; Spinal muscular atrophy; Toxicity

Indexed keywords

AMYLOID PRECURSOR PROTEIN; BETA SECRETASE 1; COPPER ZINC SUPEROXIDE DISMUTASE; DJ 1 PROTEIN; FORKHEAD TRANSCRIPTION FACTOR; HEAT SHOCK TRANSCRIPTION FACTOR 1; HUNTINGTIN; LEUCINE RICH REPEAT KINASE 2; MEMBRANE PROTEIN; PRESENILIN 1; PRESENILIN 2; PROTEIN PARK1; PROTEIN PARK11; PROTEIN PARK13; PROTEIN PARK2; PROTEIN PARK5; PROTEIN PARK6; PROTEIN PARK9; SOMATOMEDIN C; SURVIVAL MOTOR NEURON PROTEIN 1; SURVIVAL MOTOR NEURON PROTEIN 2; TAU PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; ACETYLATION; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; AMYOTROPHIC LATERAL SCLEROSIS; CAENORHABDITIS ELEGANS; DEGENERATIVE DISEASE; DISEASE MODEL; DOWN REGULATION; GENE EXPRESSION; GENE FUNCTION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC REGULATION; GENETIC SCREENING; HUNTINGTON CHOREA; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; NEUROFIBRILLARY TANGLE; NONHUMAN; ORTHOLOGY; PARKINSON DISEASE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN AGGREGATION; PROTEIN PHOSPHORYLATION; REVIEW; SENILE PLAQUE; SIGNAL TRANSDUCTION; SPINAL MUSCULAR ATROPHY; SPINOCEREBELLAR DEGENERATION; TRINUCLEOTIDE REPEAT; UBIQUITINATION;

ANIMALS; CAENORHABDITIS ELEGANS; DISEASE MODELS, ANIMAL; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEURODEGENERATIVE DISEASES;

EID: 77955841798     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2010.05.012     Document Type: Review

References (109)

1. Artal-Sanz M., Tavernarakis N. Proteolytic mechanisms in necrotic cell death and neurodegeneration. FEBS Lett. 2005, 579:3287-3296.
2. Arya U., et al. Reserpine ameliorates Abeta toxicity in the Alzheimer's disease model in Caenorhabditis elegans. Exp. Gerontol. 2009, 44:462-466.
3. Asikainen S., et al. Global microRNA expression profiling of Caenorhabditis elegans Parkinson's disease models. J. Mol. Neurosci. 2010, 41:210-218.
4. Bates G., et al. Huntington's Disease 2002, Oxford University Press. 3rd edn.
5. Bates E.A., et al. Differential contributions of Caenorhabditis elegans histone deacetylases to huntingtin polyglutamine toxicity. J. Neurosci. 2006, 26:2830-2838.
6. Bauer P.O., Nukina N. The pathogenic mechanisms of polyglutamine diseases and current therapeutic strategies. J. Neurochem. 2009, 110:1737-1765.
7. Brandt R., et al. A Caenorhabditis elegans model of tau hyperphosphorylation: induction of developmental defects by transgenic overexpression of Alzheimer's disease-like modified tau. Neurobiol. Aging 2009, 30:22-33.
8. Brenner S. The genetics of Caenorhabditis elegans. Genetics 1974, 77:71-94.
9. Briese M., et al. Deletion of smn-1, the Caenorhabditis elegans ortholog of the spinal muscular atrophy gene, results in locomotor dysfunction and reduced lifespan. Hum. Mol. Genet. 2009, 18:97-104.
10. Brignull H.R., et al. Polyglutamine proteins at the pathogenic threshold display neuron-specific aggregation in a pan-neuronal Caenorhabditis elegans model. J. Neurosci. 2006, 26:7597-7606.
11. Campion D., et al. Mutations of the presenilin I gene in families with early-onset Alzheimer's disease. Hum. Mol. Genet. 1995, 4:2373-2377.
12. Cao S., et al. Torsin-mediated protection from cellular stress in the dopaminergic neurons of Caenorhabditis elegans. J. Neurosci. 2005, 25:3801-3812.
13. Carnemolla A., et al. Rrs1 is involved in endoplasmic reticulum stress response in Huntington disease. J. Biol. Chem. 2009, 284:18167-18173.
14. Cartegni L., Krainer A.R. Disruption of an SF2/ASF-dependent exonic splicing enhancer in SMN2 causes spinal muscular atrophy in the absence of SMN1. Nat. Genet. 2002, 30:377-384.
15. Chalfie M., Wolinsky E. The identification and suppression of inherited neurodegeneration in Caenorhabditis elegans. Nature 1990, 345:410-416.
16. Chang H., et al. Modeling spinal muscular atrophy in Drosophila. PLoS ONE 2008, 15:e3209.
17. Cohen E., et al. Opposing activities protect against age-onset proteotoxicity. Science 2006, 313:1604-1610.
18. Conway K.A., et al. Acceleration of oligomerization, not fibrillization, is a shared property of both alpha-synuclein mutations linked to early-onset Parkinson's disease: implications for pathogenesis and therapy. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:571-576.
19. Cooper A.A., et al. Alpha-synuclein blocks ER-Golgi traffic and Rab1 rescues neuron loss in Parkinson's models. Science 2006, 313:324-328.
20. Crawford T.O., Pardo C.A. The neurobiology of childhood spinal muscular atrophy. Neurobiol. Dis. 1996, 3:97-110.
21. Cudkowicz M.E., et al. Epidemiology of mutations in superoxide dismutase in amyotrophic lateral sclerosis. Ann. Neurol. 1997, 41:210-221.
22. Culetto E., Sattelle D.B. A role for Caenorhabditis elegans in understanding the function and interactions of human disease genes. Hum. Mol. Genet. 2000, 9:869-877.
23. Daigle I., Li C. apl-1, a Caenorhabditis elegans gene encoding a protein related to the human beta-amyloid protein precursor. Proc. Natl. Acad. Sci. U. S. A. 1993, 90:12045-12049.
24. DiFiglia M., et al. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 1997, 277:1990-1993.
25. Driscoll M. Molecular genetics of cell death in the nematode Caenorhabditis elegans. J. Neurobiol. 1992, 23:1327-1351.
26. Faber P.W., et al. Polyglutamine-mediated dysfunction and apoptotic death of a Caenorhabditis elegans sensory neuron. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:179-184.
27. Faber P.W., et al. Glutamine/proline-rich PQE-1 proteins protect Caenorhabditis elegans neurons from huntingtin polyglutamine neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:17131-17136.
28. Feldkotter M., et al. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am. J. Hum. Genet. 2002, 70:358-368.
29. Fonte V., et al. Interaction of intracellular beta amyloid peptide with chaperone proteins. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:9439-9444.
30. Fonte V., et al. Suppression of in vivo beta-amyloid peptide toxicity by overexpression of the HSP-16.2 small chaperone protein. J. Biol. Chem. 2008, 283:784-791.
31. Fossale E., et al. Identification of a presymptomatic molecular phenotype in Hdh CAG knock-in mice. Hum. Mol. Genet. 2002, 11:2233-2241.
32. Fujiwara H., et al. alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol. 2002, 4:160-164.
33. Gidalevitz T., et al. Progressive disruption of cellular protein folding in models of polyglutamine diseases. Science 2006, 311:1471-1474.
34. Gidalevitz T., et al. Destabilizing protein polymorphisms in the genetic background direct phenotypic expression of mutant SOD1 toxicity. PLoS Genet. 2009, 5:e1000399.
35. Goedert M., Spillantini M.G. A century of Alzheimer's disease. Science 2006, 314:777-781.
36. Goedert M., et al. PTL-1, a microtubule-associated protein with tau-like repeats from the nematode Caenorhabditis elegans. J. Cell Sci. 1996, 109(Pt 11):2661-2672.
37. Gordon P., et al. The invertebrate microtubule-associated protein PTL-1 functions in mechanosensation and development in Caenorhabditis elegans. Dev. Genes Evol. 2008, 218:541-551.
38. Guthrie C.R., et al. SUT-2 potentiates tau-induced neurotoxicity in Caenorhabditis elegans. Hum. Mol. Genet. 2009, 18:1825-1838.
39. Hamamichi S., et al. Hypothesis-based RNAi screening identifies neuroprotective genes in a Parkinson's disease model. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:728-733.
40. Harrington A.J., et al. C. elegans as a model organism to investigate molecular pathways involved with Parkinson's disease. Dev. Dyn. 2010, 239:1282-1295.
41. Hassan W.M., et al. AIP-1 ameliorates beta-amyloid peptide toxicity in a Caenorhabditis elegans Alzheimer's disease model. Hum. Mol. Genet. 2009, 18:2739-2747.
42. Hutton M., et al. Association of missense and 5'-splice-site mutations in tau with the inherited dementia FTDP-17. Nature 1998, 393:702-705.
43. Jackson G.R., et al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 2002, 34:509-519.
44. Jacobsen K.T., Iverfeldt K. Amyloid precursor protein and its homologues: a family of proteolysis-dependent receptors. Cell. Mol. Life Sci. 2009, 66:2299-2318.
45. Jeong H., et al. Acetylation targets mutant huntingtin to autophagosomes for degradation. Cell 2009, 137:60-72.
46. Junn E., et al. Repression of alpha-synuclein expression and toxicity by microRNA-7. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13052-13057.
47. Kamath R.S., et al. Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 2003, 421:231-237.
48. Kashima T., Manley J.L. A negative element in SMN2 exon 7 inhibits splicing in spinal muscular atrophy. Nat. Genet. 2003, 34:460-463.
49. Kim J., et al. A MicroRNA feedback circuit in midbrain dopamine neurons. Science 2007, 317:1220-1224.
50. Kraemer B., Schellenberg G.D. Using Caenorhabditis elegans models of neurodegenerative disease to identify neuroprotective strategies. Int. Rev. Neurobiol. 2007, 77:219-246.
51. Kraemer B.C., Schellenberg G.D. SUT-1 enables tau-induced neurotoxicity in C. elegans. Hum. Mol. Genet. 2007, 16:1959-1971.
52. Kraemer B.C., et al. Neurodegeneration and defective neurotransmission in a Caenorhabditis elegans model of tauopathy. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:9980-9985.
53. Kraemer B.C., et al. Molecular pathways that influence human tau-induced pathology in Caenorhabditis elegans. Hum. Mol. Genet. 2006, 15:1483-1496.
54. Kuwahara T., et al. Familial Parkinson mutant alpha-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans. J. Biol. Chem. 2006, 281:334-340.
55. Kuwahara T., et al. A systematic RNAi screen reveals involvement of endocytic pathway in neuronal dysfunction in alpha-synuclein transgenic C. elegans. Hum. Mol. Genet. 2008, 17:2997-3009.
56. Lakso M., et al. Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human alpha-synuclein. J. Neurochem. 2003, 86:165-172.
57. Lang A.E., Lozano A.M. Parkinson's disease. First of two parts. N. Engl. J. Med. 1998, 339:1044-1053.
58. Lefebvre S., et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat. Genet. 1997, 16:265-269.
59. Levitan D., et al. Assessment of normal and mutant human presenilin function in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:14940-14944.
60. Link C.D. Expression of human beta-amyloid peptide in transgenic Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:9368-9372.
61. Link C.D. C. elegans models of age-associated neurodegenerative diseases: lessons from transgenic worm models of Alzheimer's disease. Exp. Gerontol. 2006, 41:1007-1013.
62. Link C.D., et al. Visualization of fibrillar amyloid deposits in living, transgenic Caenorhabditis elegans animals using the sensitive amyloid dye, X-34. Neurobiol. Aging 2001, 22:217-226.
63. Link C.D., et al. Gene expression analysis in a transgenic Caenorhabditis elegans Alzheimer's disease model. Neurobiol. Aging 2003, 24:397-413.
64. Liu F.H., et al. Specific interaction of the 70-kDa heat shock cognate protein with the tetratricopeptide repeats. J. Biol. Chem. 1999, 274:34425-34432.
65. Lorson C.L., et al. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:6307-6311.
66. MacDonald C.M.A., et al. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group. Cell 1993, 72:971-983.
67. McColl G., et al. The Caenorhabditis elegans A beta 1-42 model of Alzheimer disease predominantly expresses A beta 3-42. J. Biol. Chem. 2009, 284:22697-22702.
68. McDermott J.B., et al. ptl-1, a Caenorhabditis elegans gene whose products are homologous to the tau microtubule-associated proteins. Biochemistry 1996, 35:9415-9423.
69. Miguel-Aliaga I., et al. The Caenorhabditis elegans orthologue of the human gene responsible for spinal muscular atrophy is a maternal product critical for germline maturation and embryonic viability. Hum. Mol. Genet. 1999, 8:2133-2143.
70. Miyasaka T., et al. Progressive neurodegeneration in C. elegans model of tauopathy. Neurobiol. Dis. 2005, 20:372-383.
71. Morley J.F., et al. The threshold for polyglutamine-expansion protein aggregation and cellular toxicity is dynamic and influenced by aging in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10417-10422.
72. Nariai M., et al. Synergistic defect in 60S ribosomal subunit assembly caused by a mutation of Rrs1p, a ribosomal protein L11-binding protein, and 3'-extension of 5S rRNA in Saccharomyces cerevisiae. Nucleic Acids Res. 2005, 33:4553-4562.
73. Nishikori S., et al. p97 Homologs from Caenorhabditis elegans, CDC-48.1 and CDC-48.2, suppress the aggregate formation of huntingtin exon1 containing expanded polyQ repeat. Genes Cells 2008, 13:827-838.
74. Nollen E.A., et al. Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:6403-6408.
75. Oeda T., et al. Oxidative stress causes abnormal accumulation of familial amyotrophic lateral sclerosis-related mutant SOD1 in transgenic Caenorhabditis elegans. Hum. Mol. Genet. 2001, 10:2013-2023.
76. Olanow C.W., Tatton W.G. Etiology and pathogenesis of Parkinson's disease. Annu. Rev. Neurosci. 1999, 22:123-144.
77. Ozelius L.J., et al. The early-onset torsion dystonia gene (DYT1) encodes an ATP-binding protein. Nat. Genet. 1997, 17:40-48.
78. Paisan-Ruiz C., et al. Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 2004, 44:595-600.
79. Park K.W., Li L. Cytoplasmic expression of mouse prion protein causes severe toxicity in Caenorhabditis elegans. Biochem. Biophys. Res. Commun. 2008, 372:697-702.
80. Parker J.A., et al. Expanded polyglutamines in Caenorhabditis elegans cause axonal abnormalities and severe dysfunction of PLM mechanosensory neurons without cell death. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:13318-13323.
81. Parker J.A., et al. Resveratrol rescues mutant polyglutamine cytotoxicity in nematode and mammalian neurons. Nat. Genet. 2005, 37:349-350.
82. Parker J.A., et al. Huntingtin-interacting protein 1 influences worm and mouse presynaptic function and protects Caenorhabditis elegans neurons against mutant polyglutamine toxicity. J. Neurosci. 2007, 27:11056-11064.
83. Pearn J. Incidence, prevalence, and gene frequency studies of chronic childhood spinal muscular atrophy. J. Med. Genet. 1978, 15:409-413.
84. Polymeropoulos M.H., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 1997, 276:2045-2047.
85. Ruan Q., et al. VPS41, a protein involved in lysosomal trafficking, is protective in Caenorhabditis elegans and mammalian cellular models of Parkinson's disease. Neurobiol. Dis. 2010, 37:330-338.
86. Saha S., et al. LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J. Neurosci. 2009, 29:9210-9218.
87. Satyal S.H., et al. Polyglutamine aggregates alter protein folding homeostasis in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:5750-5755.
88. Selkoe D.J. Amyloid beta-protein and the genetics of Alzheimer's disease. J. Biol. Chem. 1996, 271:18295-18298.
89. Sharma N., et al. A close association of torsinA and alpha-synuclein in Lewy bodies: a fluorescence resonance energy transfer study. Am. J. Pathol. 2001, 159:339-344.
90. Sherrington R., et al. Alzheimer's disease associated with mutations in presenilin 2 is rare and variably penetrant. Hum. Mol. Genet. 1996, 5:985-988.
91. Singleton A.B., et al. alpha-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302:841.
92. Spillantini M.G., et al. Mutation in the tau gene in familial multiple system tauopathy with presenile dementia. Proc. Natl. Acad. Sci. U. S. A. 1998, 95:7737-7741.
93. Springer W., et al. A Caenorhabditis elegans Parkin mutant with altered solubility couples alpha-synuclein aggregation to proteotoxic stress. Hum. Mol. Genet. 2005, 14:3407-3423.
94. Stanhill A., et al. An arsenite-inducible 19S regulatory particle-associated protein adapts proteasomes to proteotoxicity. Mol. Cell 2006, 23:875-885.
95. Stege G.J., et al. The molecular chaperone alphaB-crystallin enhances amyloid beta neurotoxicity. Biochem. Biophys. Res. Commun. 1999, 262:152-156.
96. Sym M., et al. A model for Niemann-Pick type C disease in the nematode Caenorhabditis elegans. Curr. Biol. 2000, 10:527-530.
97. Szebenyi G., et al. Hook2 contributes to aggresome formation. BMC Cell Biol. 2007, 8:19.
98. Teschendorf D., Link C.D. What have worm models told us about the mechanisms of neuronal dysfunction in human neurodegenerative diseases?. Mol. Neurodegener. 2009, 4:38.
99. van Ham T.J., et al. C. elegans model identifies genetic modifiers of alpha-synuclein inclusion formation during aging. PLoS Genet. 2008, 4:e1000027.
100. Voisine C., et al. Identification of potential therapeutic drugs for huntington's disease using Caenorhabditis elegans. PLoS One 2007, 2:e504.
101. Wang H., et al. Suppression of polyglutamine-induced toxicity in cell and animal models of Huntington's disease by ubiquilin. Hum. Mol. Genet. 2006, 15:1025-1041.
102. Wang H., et al. Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum. Mol. Genet. 2009, 18:737-752.
103. Wang J., et al. An ALS-linked mutant SOD1 produces a locomotor defect associated with aggregation and synaptic dysfunction when expressed in neurons of Caenorhabditis elegans. PLoS Genet. 2009, 5:e1000350.
104. White J.G., et al. The structure of the nervous system of the nematode C. elegans. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1986, 314:1-340.
105. Wu Y., et al. Amyloid-beta-induced pathological behaviors are suppressed by Ginkgo biloba extract EGb 761 and ginkgolides in transgenic Caenorhabditis elegans. J. Neurosci. 2006, 26:13102-13113.
106. Wu Y., et al. Heat shock treatment reduces beta amyloid toxicity in vivo by diminishing oligomers. Neurobiol. Aging 2010, 31:1055-1058.
107. Yamanaka K., et al. Analysis of the two p97/VCP/Cdc48p proteins of Caenorhabditis elegans and their suppression of polyglutamine-induced protein aggregation. J. Struct. Biol. 2004, 146:242-250.
108. Yun C., et al. Proteasomal adaptation to environmental stress links resistance to proteotoxicity with longevity in Caenorhabditis elegans. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:7094-7099.
109. Zimprich A., et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004, 44:601-607.